Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's rival treatment Wegovy, which are peptide mimics of the appetite-controlling hormone GLP-1
What this all means for supplements is complex
I am not going to complain about the dosage at all - its spot on where it should be
Lab work may be recommended to evaluate metabolic function and identify contributing factors
"Obesity is a difficult-to-manage disease, and it's even more difficult for people living with type 2 diabetes," Jeff Emmick, MD, PhD, senior vice president, product development, Lilly, said in a statement
Participants were randomized to increasing doses of once-weekly semaglutide or placebo